Literature DB >> 27997989

Effects of an intensive lifestyle intervention program on portal hypertension in patients with cirrhosis and obesity: The SportDiet study.

Annalisa Berzigotti1,2,3, Agustín Albillos1,4, Candid Villanueva1,5, Joan Genescá1,6, Alba Ardevol1,5, Salvador Augustín1,6, Jose Luis Calleja1,7, Rafael Bañares1,8, Juan Carlos García-Pagán1,2, Francisco Mesonero1,4, Jaime Bosch1,2,3.   

Abstract

Obesity increases the risk of clinical decompensation in cirrhosis, possibly by increasing portal pressure. Whether weight reduction can be safely achieved through lifestyle (LS) changes (diet and exercise) in overweight/obese patients with cirrhosis, and if weight loss reduces portal pressure in this setting, is unknown. This prospective, multicentric, uncontrolled pilot study enrolled patients with compensated cirrhosis, portal hypertension (hepatic venous pressure gradient [HVPG] ≥6 mm Hg), and body mass index (BMI) ≥26 kg/m2 in an intensive 16-week LS intervention program (personalized hypocaloric normoproteic diet and 60 min/wk of supervised physical activity). We measured HVPG, body weight (BW) and composition, adipokines, health-related quality of life, and safety data before and after the intervention. Changes in HVPG and BW were predefined as clinically relevant if ≥10% and ≥5%, respectively. Safety and BW were reassessed after 6 months. 60 patients were included and 50 completed the study (56 ± 8 years old; 62% male; nonalcoholic steatohepatitis etiology 24%; BMI 33.3 ± 3.2 kg/m2 ; Child A 92%; HVPG ≥10 mm Hg, 72%). LS intervention significantly decreased BW (average, -5.0 ± 4.0 kg; P < 0.0001), by ≥5% in 52% and ≥10% in 16%. HVPG also significantly decreased (from 13.9 ± 5.6 to 12.3 ± 5.2 mm Hg; P < 0.0001), by ≥10% in 42% and ≥20% in 24%. A ≥10% BW loss was associated with a greater decrease in HVPG (-23.7 ± 19.9% vs. -8.2 ± 16.6%; P = 0.024). No episodes of clinical decompensation occurred. Weight loss achieved at 16 weeks was maintained at 6 months; Child and Model for End-Stage Liver Disease scores did not change.
CONCLUSION: Sixteen weeks of diet and moderate exercise were safe and reduced BW and portal pressure in overweight/obese patients with cirrhosis and portal hypertension. (Hepatology 2017;65:1293-1305).
© 2016 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2017        PMID: 27997989     DOI: 10.1002/hep.28992

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  56 in total

Review 1.  Nutritional Intervention in Chronic Liver Failure.

Authors:  Mathias Plauth
Journal:  Visc Med       Date:  2019-08-21

2.  A North American Expert Opinion Statement on Sarcopenia in Liver Transplantation.

Authors:  Elizabeth J Carey; Jennifer C Lai; Christopher Sonnenday; Elliot B Tapper; Puneeta Tandon; Andres Duarte-Rojo; Michael A Dunn; Cynthia Tsien; Eric R Kallwitz; Vicky Ng; Srinivasan Dasarathy; Matthew Kappus; Mustafa R Bashir; Aldo J Montano-Loza
Journal:  Hepatology       Date:  2019-08-19       Impact factor: 17.425

3.  ESPEN guideline on clinical nutrition in liver disease.

Authors:  Mathias Plauth; William Bernal; Srinivasan Dasarathy; Manuela Merli; Lindsay D Plank; Tatjana Schütz; Stephan C Bischoff
Journal:  Clin Nutr       Date:  2019-01-16       Impact factor: 7.324

4.  The Association of Hispanic Ethnicity with Nonalcoholic Fatty Liver Disease in Polycystic Ovary Syndrome.

Authors:  Monika Sarkar; Norah Terrault; Caroline C Duwaerts; Phyllis Tien; Marcelle I Cedars; Heather Huddleston
Journal:  Curr Opin Gynecol Obstet       Date:  2018-04-05

5.  The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease.

Authors:  Mohammed Eslam; Shiv K Sarin; Vincent Wai-Sun Wong; Jian-Gao Fan; Takumi Kawaguchi; Sang Hoon Ahn; Ming-Hua Zheng; Gamal Shiha; Yusuf Yilmaz; Rino Gani; Shahinul Alam; Yock Young Dan; Jia-Horng Kao; Saeed Hamid; Ian Homer Cua; Wah-Kheong Chan; Diana Payawal; Soek-Siam Tan; Tawesak Tanwandee; Leon A Adams; Manoj Kumar; Masao Omata; Jacob George
Journal:  Hepatol Int       Date:  2020-10-01       Impact factor: 6.047

Review 6.  Hyperammonemia and proteostasis in cirrhosis.

Authors:  Srinivasan Dasarathy; Maria Hatzoglou
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2018-01       Impact factor: 4.294

Review 7.  Pharmacologic prevention of variceal bleeding and rebleeding.

Authors:  Anna Baiges; Virginia Hernández-Gea; Jaime Bosch
Journal:  Hepatol Int       Date:  2017-12-05       Impact factor: 6.047

8.  Exercise and physical activity in cirrhosis: opportunities or perils.

Authors:  Annette Bellar; Nicole Welch; Srinivasan Dasarathy
Journal:  J Appl Physiol (1985)       Date:  2020-04-02

Review 9.  EASL Clinical Practice Guidelines on nutrition in chronic liver disease.

Authors: 
Journal:  J Hepatol       Date:  2018-08-23       Impact factor: 25.083

Review 10.  Peri-transplant management of nonalcoholic fatty liver disease in liver transplant candidates .

Authors:  Naga Swetha Samji; Rajiv Heda; Sanjaya K Satapathy
Journal:  Transl Gastroenterol Hepatol       Date:  2020-01-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.